Tricuspid valve disease and cardiac implantable electronic devices.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38096587.
- Also identified by DOI 10.1093/eurheartj/ehad783 and PMC identifier 10834167.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The role of cardiac implantable electronic device (CIED)-related tricuspid regurgitation (TR) is increasingly recognized as an independent clinical entity. Hence, interventional TR treatment options continuously evolve, surgical risk assessment and peri-operative care improve the management of CIED-related TR, and the role of lead extraction is of high interest. Furthermore, novel surgical and interventional tricuspid valve treatment options are increasingly applied to patients suffering from TR associated with or related to CIEDs. This multidisciplinary review article developed with electrophysiologists, interventional cardiologists, imaging specialists, and cardiac surgeons aims to give an overview of the mechanisms of disease, diagnostics, and proposes treatment algorithms of patients suffering from TR associated with CIED lead(s) or leadless pacemakers.
Medical subject headings
- Pacemaker, Artificial
- Defibrillators, Implantable
- Tricuspid Valve Insufficiency
- Rheumatic Heart Disease